COMMUNIQUÉS West-GlobeNewswire

Now Available: Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor
13/03/2026
MOORESVILLE, N.C., March 13, 2026 (GLOBE NEWSWIRE) -- The Hemp Doctor introduces the Fresh Bloom THCA Flower Subscription Box , a monthly drop of hand-selected flower and pre-rolls delivered to your door, including [...]
Novonesis issues EUR 1.7 billion senior unsecured notes
13/03/2026
On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly [...]
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
13/03/2026
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes [...]
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
13/03/2026
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/03/2026
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical [...]
BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results
12/03/2026
LONG BEACH, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the full year [...]
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint [...]
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
12/03/2026
TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA to patients, [...]
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
12/03/2026
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI [...]
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/03/2026
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation [...]
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
12/03/2026
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was [...]
GlycoPezil Supplement Claims Evaluated - Complete Investigation of the Blood Sugar Support Ingredients
12/03/2026
A 2026 consumer research report examining GlycoPezil's ingredient research references, proprietary blend structure, pricing transparency, and verification considerations for adults researching blood sugar support [...]
Health Catalyst Reports Fourth Quarter and Year End 2025 Results
12/03/2026
SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin [...]
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
12/03/2026
MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on [...]
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib [...]
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
12/03/2026
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation [...]
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
12/03/2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
12/03/2026
Conference Call to be held on April 2nd, 2026 at 5:00 PM EST NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4 and year end [...]

Pages